Helicobacter pylori as a class I carcinogen: Physiopathology and management strategies

Journal of Cellular Biochemistry

Volumn 102, Issue 2, 2007, Pages 264-273

  Vogiatzi, Paraskevi ^a,c   Cassone, Marco ^a,c   Luzzi, Ida ^b   Lucchetti, Chiara ^a,c   Otvos Jr , Laszlo ^a   Giordano, Antonio ^a,c  

^a Temple University   (United States)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Antibiotics; Gastric cancer; H. pylori; Prevention; Vaccines

Indexed keywords

AMOXICILLIN; BISMUTH SALICYLATE; CIMETIDINE; CLARITHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LACTOFERRIN; LANSOPRAZOLE; METRONIDAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BITTER TASTE; CARCINOGENIC ACTIVITY; ERADICATION THERAPY; FECES; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SIDE EFFECT; STOMACH CANCER;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BACTERIAL VACCINES; CANCER VACCINES; DRUG RESISTANCE, BACTERIAL; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; PEPTIC ULCER; STOMACH NEOPLASMS;

ANIMALIA; AVES; HELICOBACTER PYLORI; NEGIBACTERIA;

EID: 34948821738     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21375     Document Type: Review

References (49)

1. Algood HM, Cover TL. 2006. Helicobacter pylori persistence: An overview of interactions between H. pylori and host immune defenses. Clin Microbiol Rev 19:597-613.
2. Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ. 1999. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397:176-180.
3. Bizzozero G. 1892. Sulle ghiandole tubulari del tubo gastroenterico e sui rapporti del loro epitelio di rivestimento della mucosa. Atti R Accad Sci Torino 28:233-251.
4. Blaser MJ. 2005. The biology of cag in the Helicobacter pylori-human interaction. Gastroenterology 128:1512-1515.
5. Borody TJ, Pang G, Wettstein AR, Clancy R, Herdman K, Surace R, Llorente R, Ng C. 2006. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 23:481-488.
6. Cassone M, Giordano A, Pozzi G. 2007. Bacterial DNA microarrays for clinical microbiology: The early logarithmic phase. Front Biosci 12:2658-2669.
7. Chen M, Lee A, Hazell S. 1992. Immunisation against gastric helicobacter infection in a mouse/Helicobacter felis model. Lancet 339:1120-1121.
8. Dai G, Cheng N, Dong L, Muramatsu M, Xiao S, Wang MW, Zhu DX. 2005. Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori. Antimicrob Agents Chemother 49: 3468-3473.
9. De Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, Mumolo MG, Ricchiuti A, Cristiani F, Santi S, Rossi M, Marchi S. 2007. Helicobacter pylori eradication: A randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 102:1-6.
10. Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. 1995. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 92:6499-6503.
11. Ford AC, Delaney BC, Forman D, Moayyedi P. 2004. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: Systematic review and economic analysis. Am J Gastroenterol 99:1833-1855.
12. Fox JG, Beck P, Dangler CA, Whary MT, Wang TC, Shi HN, Nagler-Anderson C. 2000. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med 6:536-542.
13. Frenck RW, Jr, Clemens J. 2003. Helicobacter in the developing world. Microbes Infect 5:705-713.
14. Garrity GM, Bell JA, Lilburn T. 2005. Class V. Epsilonproteobacteria class. nov. In: Brenner DJ, Krieg NR, Staley JT, Garrity GM, editors. Bergey's manual of systematic bacteriology, 2nd edition, Vol. 2(The Proteobacteria), part C (The Alpha-, Beta-, Delta-, and Epsilonproteobacteria). New York: Springer. 1145 p.
15. Gerhard M, Lehn N, Neumayer N, Boren T, Rad R, Schepp W, Miehlke S, Classen M, Prinz C. 1999. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. Proc Natl Acad Sci USA 96: 12778-12783.
16. Gerrits MM, van Vliet AH, Kuipers EJ, Kusters JG. 2006. Helicobacter pylori and antimicrobial resistance: Molecular mechanisms and clinical implications. Lancet Infect Dis 6:699-709.
17. Gisbert JP, Abraira V. 2006. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: A systematic review and meta-analysis. Am J Gastroenterol 101:848-863.
18. Hatzifoti C, Roussel Y, Harris AG, Wren BW, Morrow JW, Bajaj-Elliott M. 2006. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Helicobacter 11:113-122.
19. Hessey SJ, Spencer J, Wyatt JI, Sobala G, Rathbone BJ, Axon AT, Dixon MF. 1990. Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis. Gut 31:134-138.
20. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. 2004. Gastric cancer originating from bone marrow-derived cells. Science 306:1568-1571.
21. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. 2003. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 125: 1636-1644.
22. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. 1994. Lyon, 7-14 June 1994. Schistosomes, liver flukes, and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 61:1-241.
23. Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Boren T. 1998. Helicobacter pylori adhesin binding fucosylated histoblood group antigens revealed by retagging. Science 279: 373-377.
24. Jeong JY, Mukhopadhyay AK, Akada JK, Dailidiene D, Hoffman PS, Berg DE. 2001. Roles of FrxA and RdxA nitroreductases of Helicobacter pylori in susceptibility and resistance to metronidazole. J Bacteriol 183:5155-5162.
25. Kragol G, Hoffmann R, Chattergoon MA, Lovas S, Cudic M, Bulet P, Condie BA, Rosengren KJ, Montaner LJ, Otvos L, Jr. 2002. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur J Biochem 269:4226-4237.
26. Kreiss C, Buclin T, Cosma M, Corthesy-Theulaz I, Michetti P. 1996. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet 347:1630-1631.
27. Kusters JG, van Vliet AH, Kuipers EJ. 2006. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 19: 449-490.
28. Lugli A, Zlobec I, Singer G, Kopp Lugli A, Terracciano LM, Genta RM. 2007. Napoleon Bonaparte's gastric cancer: A clinicopathologic approach to staging, pathogenesis, and etiology. Nat Clin Pract Gastroenterol Hepatol 4:52-57.
29. Luzzi I, Pezzella C, Caprioli A, Covacci A, Bugnoli M, Censini S. 1993. Detection of vacuolating toxin of Helicobacter pylori in human faeces. Lancet 341:1348.
30. Malfertheiner P, Megraud F, O'morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. 2007. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 56:772-781.
31. Marchetti M, Arico B, Burroni D, Figura N, Rappuoli R, Ghiara P. 1995. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 267:1655-1658.
32. Marshall BJ, Warren JR. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1:1311-1315.
33. Marwick C. 1990. Helicobacter: New name, new hypothesis involving type of gastric cancer. JAMA 264:2724. 2727.
34. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, Herranz M, Saldinger PF, Corthesy-Theulaz I, Losonsky G, Nichols R, Simon J, Stolte M, Ackerman S, Monath TP, Blum AL. 1999. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116:804-812.
35. Mini R, Bernardini G, Salzano AM, Renzone G, Scaloni A, Figura N, Cantucci A. 2006. Comparative proteomics and immunoproteomics of Helicobacter pylori related to different gastric pathologies. J Chromatogr B Analyt Technol Biomed Life Sci 833:63-79.
36. Ogura K, Maeda S, Nakao M, Watanabe T, Tada M, Kyutoku T, Yoshida H, Shiratori Y, Omata M. 2000. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J Exp Med 192: 1601-1610.
37. Oh JD, Karam SM, Gordon JI. 2005. Intracellular Helicobacter pylori in gastric epithelial progenitors. Proc Natl Acad Sci USA 102:5186-5191.
38. Palli D, Saieva C, Luzzi I, Masala G, Topa S, Sera F, Gemma S, Zanna I, D'Errico M, Zini E, Guidotti S, Valeri A, Fabbrucci P, Moretti R, Testai E, del Giudice G, Ottini L, Matullo G, Dogliotti E, Gomez-Miguel MJ. 2005. Interleukin-1 gene polymorphisms and gastric cancer risk in a high-risk Italian population. Am J Gastroenterol 100:1941-1948.
39. Rad R, Schmid RM, Prinz C. 2006. Helicobacter pylori, iron deficiency, and gastric autoimmunity. Blood 107:4969-4970.
40. Resnick MB, Sabo E, Meitner PA, Kim SS, Cho Y, Kim HK, Tavares R, Moss SF. 2006. Global analysis of the human gastric epithelial transcriptome altered by Helicobacter pylori eradication in vivo. Gut 55:1717-1724.
41. Saldinger PF, Porta N, Launois P, Louis JA, Waanders GA, Bouzourene H, Michetti P, Blum AL, Corthesy-Theulaz IE. 1998. Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection. Gastroenterology 115:891-897.
42. Serruto D, Rappuoli R. 2006. Post-genomic vaccine development. FEBS Lett 580:2985-2992.
43. Stolte M. 1992. Helicobacter pylori gastritis and gastric MALT-lymphoma. Lancet 339:745-746.
44. Suerbaum S, Michetti P. 2002. Helicobacter pylori infection. N Engl J Med 347:1175-1186.
45. Takahashi T, Yujiri T, Tanizawa Y. 2004. Helicobacter pylori and chronic ITP: The discrepancy in the clinical responses to eradication therapy might be due to differences in the bacterial strains. Blood 104:594.
46. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC. 1997. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388:539-547.
47. Vogiatzi P, Vindigni C, Roviello F, Renieri A, Giordano A. 2007. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol 211:287-295.
48. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyren O. 2004. Helicobacter pylori infection and gastric atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 96:388-396.
49. Zavala-Spinetti L, Breslin MB, Correa H, Begue RE. 2006. Development and evaluation of a DNA vaccine based on Helicobacter pylori urease B: Failure to prevent experimental infection in the mouse model. Helicobacter 11:517-522.